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Abstract— In this work, we showed the realization of a fully-
implantable device that integrates a microfabricated sensing
platform, a coil for power and data transmission and integrated
circuits. We described a device intended to test the biocompati-
bility of the materials used for the microfabrication. Therefore,
electronics measurements for data communication and remote
powering will be reported in another article [1]. To ensure
biocompatibility an epoxy enhanced polyurethane membrane
was used to cover the device. We proved through an in-vitro
characterization that the membrane was capable to retain enzyme
activity up to 35 days. After 30 days of implant in mice, in-vivo
experiments proved that the membrane promotes the integration
of the sensor with the surrounding tissue, as demonstrated by
the low inflammation level at the implant site.
I. INTRODUCTION
Electrochemical sensors for real-time monitoring of glucose
and lactate are already in the market [2], moreover for glu-
cose, first prototypes of fully implantable sensors have been
validated up to 8 months in mice [3] and up to one year in pigs
[4]. The development of an implantable device for monitoring
exogenous substances, such as drugs and other important
metabolites, would represent a big step towards personalized
medicine. A device capable to monitor multiple substances
should contain an array of sensors with enough sensitivity to
monitor drugs and metabolites within the therapeutic range.
Moreover, an implantable device should be autonomous with
respect to the power supply of the data transmission block
and of the sensor block including its electronic front-end.
The biocompatibility and the sensor stability in time are
other fundamental issues for implantable devices: the sensor
should be well tolerated by the host and cause a limited
foreign body reaction, and at the same time the contact with
biological fluids should not significantly affect sensor perfor-
mances [5]. The sensor performance may be also improved
using nanostructured materials. Excellent performances have
been obtained by using carbon nanotubes [6], metallic [7] or
semiconducting [8] quantum dots or other nano-materials [9].
However, since carbon nanotubes may be potentially toxic, the
biocompatibility of devices incorporating nanomaterials needs
to be investigated.
The present work focuses on the design and fabrication of a
prototype for a fully-implantable device that consists of: 1) a
passive sensing platform, 2) integrated circuits to perform elec-
trochemical measurements and 3) a coil for autonomy power
transmission. We show the assembly of these components and
the use of an innovative biocompatible packaging based on an
epoxy enhanced polyurethane membrane. To test the properties
of the membrane, we performed in-vitro characterization on
screen-printed electrodes (SPEs) and in-vivo biocompatibility
tests, by implanting the devices in mice for 30 days.
II. MATERIALS AND METHODS
A. Passive Chip Microfabrication
Microfabrication was realized at the EPFL Centre of Mi-
cronano Technology (CMI). Silicon wafers with 500 nm of
native oxide were chosen as substrate. Chip metalization was
realized by evaporation of 10 nm of Ti, followed by 100 nm
of Pt. Metal passivation was made via atomic layer deposition
of Al2O3, followed by dry etching with Argon Ion Milling.
Details on the microfabrication can be found in [10].
B. Sensors Functionalization and Membrane Deposition
We performed electrochemical measurements with both
carbon paste screen-printed electrodes (SPEs, model DRP-
110, DropSens) and the microfabricated passive platform.
The working electrode of SPEs was nanostructured with
30 µg multi-walled carbon nanotubes (MWCNTs, purchased
by Dropsens), as reported in [11]. For the microfabricated
platform, the working electrodes were functionalized by elec-
trodeposition of a chitosan/MWCNT dispersion 8 mg/ml, pH
5, by applying a fixed potential of 1.5 V for 2400 s [10]. A
solution of glucose oxidase enzyme (from Roche) in phosphate
buffered saline (PBS) 1X pH 5.8, was drop cast on the working
electrodes and stored overnight at 4°C.
An epoxy polyurethane membrane was employed as protec-
tive membrane for the sensor [3]. A homogeneous solution
was obtained by mixing 12.5 mg of an epoxy adhesive
(EP42HT-2Med system), purchased by Master Bond as a
certified biocompatible two-components adhesive, 12 mg of
Polyurethane (PU, Sigma Aldrich), 1 mg of the surfactant
agent Polyethylene glycol ether (Brij® 30, Sigma Aldrich), for
1 ml of Tetrahydrofuran (THF, Sigma Aldrich) used as solvent.
The deposition method is known as dip coating and it consists
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of a quick immersion of the sensor in the membrane solution.
Subsequent depositions were applied at 2 h intervals and then
the sensors were stored overnight at room temperature. A fast
curing at high temperature (80°C) is needed to ensure the
biocompatibility of the resin. After this process the sensors
were again kept overnight at room temperature, and then stored
in PBS one day for membrane swelling. When not in use, the
sensors were stored in PBS at room temperature.
C. Electrochemical Measurements
Electrochemical measurements were performed using an
Autolab electrochemical workstation (Metrohm). Electrodes
were tested for glucose sensitivity with chronoamperometry at
+650 mV. The sensors were first dipped in a 1X PBS solution
(pH 7.4), under stirring conditions, then conditioned for 1 h at
+650 mV and then tested against repeated injections of glucose
100 µM. Sensitivity per unit area and limit of detection (LOD)
were computed from the straight line obtained by plotting the
current vs. glucose concentration, according to [11], [12].
D. Integrated Device Assembly and Packaging
The epoxy adhesive (EP42HT-2Med system) was used to
assembly the electronic component in the integrated device.
The interconnections between the pads of the passive chip and
electronic components were realized with Al wire bonding and
were protected with a glob top protection of 0.3 mm. All the
edges of the device were rounded with a milling machine.
Two subsequent 5 µm layers of Parylene C were deposited by
chemical vapor deposition using a Comelec C-30-S Parylene
Deposition System. Parylene C was used to cover the whole
device but not the electrode array that needs to be in contact
with fluids.
E. In-vivo biocompatibility
Microchips were cleaned and disinfected with ethanol 70%
and placed in sterile PBS (Gibco) for 24 h to stabilize the
membrane. An Air Pouch (AP) was created by subcutaneous
injection of sterile air in the back of male C57BL/6 mice at
day 1 (5 mL) and day 3 (3 mL): this procedure creates a cavity
of 1.5 cm diameter and 0.5 cm height. At day 6, mice were
anesthetized with isoflurane 4%, shaved and locally sterilized
with Betadine solution; the sterile microchips were implanted
and the cavity sutured with Vicryl 6.0 (Provet AG). As a
control of local inflammation, bacterial lipopolysaccharide
(LPS) (50 µg/mouse) (LabForce AG) was injected daily into
the cavity for the last 2 weeks of the 30 days of the experiment.
As negative control APs were generated in the absence of
any surgical procedure. As further control commercial chips
(DATA MARS) were injected through sterile needle. After 30
days, the microchips were removed. The cavity was rinsed
with 0.5 mL of PBS (Gibco) and the liquid collected and
centrifuged at 7000 rpm for 10 min at 4°C. The concentration
of ATP was determined in the supernatant with ATP deter-
mination kit (Invitrogen). For polymorphonuclear neutrophils
detection, the pellet was resuspended in 0.2 mL RPMI 10%
fetal bovine serum (Gibco) and analyzed at flow cytometer
(FACS Canto, Becton Dickinson) with antibodies specific for
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Fig. 1. Photographs of the microfabricated platform (center), with the three
geometries for the working electrode (WE), the pads for integration with ICs
and the pH sensor and the temperature sensor.
CD11b and Gr1, labelled with allophycocyanin (APC) and
fluorescein isothiocyanate (FITC) (BioLegend), respectively.
III. RESULTS AND DISCUSSION
A. Implantable sensor design and fabrication
1) Design and fabrication of the passive chip: The mi-
crofabrication of the passive chip was realized with a two-
masks process flow. Details on the process flow can be found
in [10]. The design of the passive chip was done under
the constraints given by the compatibility with the other
components. The platform measures 12x11 mm in order to
fit the size of the coil (12x12 mm) and the wire bonding.
Fig. 1 shows the photograph of the passive chip with the main
structures. The platform hosts an array of four independent
cells in the three-electrode configuration (working electrode
(WE), counter electrode (CE) and a reference electrode (RE)).
Working electrodes were realized in three different geometries
(diameter of 500 µm, 1 mm and 1.2 mm). A pH sensor and
a temperature sensor were fabricated in Pt. The pH sensor
has a WE with a 300 µm diameter and it is based on an
anodic iridium oxide film as reported in [10]. The resistive
thermal device (RTD) consists of a Pt coil (4 nm width
and 93 nm length) with an average resistivity of 35 kΩ
at 20°C, compatible with the power constraints. The main
advantage behind the design of an array of independent sensors
is the possibility to perform multiplexed measurements of
drugs or metabolites. The design of a sensing platform for
electrochemical measurement, combined with the presence of
a pH and a temperature sensor, is a strategy to optimize
the sensing performance in different physiological conditions,
since changes in pH and temperature can affect the sensor
specificity, e.g. in drug detection [13].
2) Measurement IC: A configurable integrated circuit has
been designed and fabricated in 180 nm technology to control
and readout the biosensor array. Readout circuit for the pH
sensor and Pt-RTD are also integrated [14]. The readout IC
will be powered by the power management IC.
3) Power Management: The power is transferred to the
battery-less implanted system via an optimized inductively
coupled power link over 30 mm distance. Fig. 2 (a) shows
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Fig. 2. Components of the implantable device.
the optimized inductively coupled power link. The sizes of
the powering and implanted coils are 80x80 mm and 12x12
mm respectively. The supply voltage of the overall system is
generated by the power management circuits located above the
implanted coil as shown in Fig. 2 (a). The power management
circuits include the full-wave passive rectifier and the high-
speed voltage regulator to supply a clean and stable 1.8 V
supply voltage [15]. The biosensor system is intended to
be implanted inside a freely moving animal. Therefore, an
Intelligent Remote Powering (IRPower) system is designed
to monitor the animal in the cage [16], and to adapt the
transferred power level according to the position of the animal.
Fig. 2 (b) shows the components of the implantable device, and
the assembly steps: the integrated circuits and the coil (A) are
glued together with the passive chip (B) and Al wire bonding is
realized. After the mechanical milling of the edges the device
is coated with Parylene C, electrodes are functionalized with
MWCNTs and the device is covered with three layers of a
biocompatible membrane (C) as described in the next section.
B. Biocompatible Packaging
Potential sources of inflammation for implantable devices
are attributed to the materials, shape and sizes of the devices
[5]. MWCNTs were entrapped in a chitosan matrix to prevent
toxicity due to the nano-particle nature of the MWCNTs
and residues of the catalysts as well. To prevent leaking of
potential hazardous substances and the corrosion of electronic
components in contact with biologic fluids, a 10-µm coating
of Parylene C was employed [10]. For an implantable sensor,
the development of a biocompatible packaging is essential
for promoting wound healing, and ensuring prolonged sensor
functionality. Most of biocompatible packaging from literature
[9] require a mold (e.g. for packaging in PDMS) or the
application of an additional membrane (e.g. polycarbonate
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Fig. 3. Heat and membrane thickness effects on the sensor sensitivity (Error
bars: standard error of three different SPE-based biosensors).
membrane) that results in many manipulation steps that could
affect the final biocompatibility grade. In this work, we de-
veloped a biocompatible packaging using an epoxy enhanced
polyurethane membrane tested for the first time by Yu et
al. [3]. Moreover the porosity of the membrane controls the
passage of analytes to the electrodes, without the need of an
additional membrane.
1) Membrane characterization and measurements: In-vitro
characterization of the membrane was performed on carbon-
paste SPEs, in order to assess the optimized number of
membrane layers and to understand the membrane effect on
enzyme activity. After the functionalization with MWCNTs
and glucose oxidase, electrodes were covered with 1-2-3 layers
of the membrane, and finally tested for glucose sensitivity
with chronoamperometry at +650 mV. Fig. 3 reports the
effect of the curing temperature and membrane thickness on
sensor sensitivity. The high temperature effect on biosensors
without any membrane was investigated, showing a decrease
in sensitivity probably due to a partial enzyme denaturation.
However LOD was lower after the curing (18±1 µM) com-
pared to the case of a SPE-MWCNT/GOD biosensor (73±8
µM), due to a reduction of the standard deviation of the
background signal (data not shown). Last columns in Fig. 3
show that the application of one layer of membrane does
not significantly change sensor performances, probably due
to a not homogeneous coating. Two and three layers decrease
the sensor sensitivity and increase the LOD (90±23 µM and
72.0±0.7 µM respectively), but are the best trade-off between
the decrease of sensitivity and a homogeneous cover. We
also performed chronoamperometry with our microfabricated
passive chip. Working electrodes of 1.2 mm diameter, modified
with MWCNTs in chitosan and glucose oxidase, were covered
with 2-3 layers of the membrane. All the chips were tested
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Fig. 4. Long term stability of a biosensor coated by 2 membrane layers
(Error bars: standard error of two measurements on each day).
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Fig. 5. ATP concentrations (nM) and percentages of neutrophils recovered
from APs treated as indicated.
for glucose sensitivity with chronoamperometry at +650 mV,
and the sensitivity was then compared. Without any membrane
we obtained a sensitivity of 63±15 µA/mM· cm2 and a LOD
of 8±2 µM. With 2 layers of the membrane we obtained
a lower sensitivity (28±4 µA/mM· cm2) but a lower LOD
(6±4 µM) due again to reduction of the standard deviation
of the background signal. Similarly to SPE based sensor, the
addition of a third membrane layer does not significantly
affect the sensor performances: with 3 layers we obtained a
sensitivity of 29±1 µA/mM· cm2 and a LOD of 7±4 µM.
The long term stability of the coated biosensor was evaluated
by chronoamperometry for glucose sensitivity on SPEs for 40
days. The work in [17] reported a long term stability of 24
days using the same SPE and glucose oxidase immobilized by
adsorption onto MWCNT-working electrode. Fig. 4 shows that
with two layers of epoxy enhanced polyurethane membrane
the sensitivity slightly decreases with respect to time; the
relative variation is equal to 28% after 35 days.
2) Biocompatibility in-vivo tests: In order to investigate
the in-vivo biocompatibility of the implantable sensor, we
subcutaneously implanted four prototypes in mice for 30 days.
At the end of the period, the implant site was washed with
PBS, and levels of ATP and neutrophils in the elution liquid
were quantified to follow the local inflammatory response.
Changes in ATP concentration and changes in neutrophils
percentage give information on the local cell death and on
the status of tissue inflammation, respectively. Fig. 5 reports
ATP and neutrophil variations in the liquid collected from the
implant site. ATP and neutrophil levels were also evaluated
for a commercial chip (DATA MARS), in case of induced
inflammation (LPS) and for the negative control (mice with
AP). For the negative control, the neutrophil level is zero
while there is still a small amount of extracellular ATP due
to the small wound created by the air pouch. Data from
both neutrophil infiltration and ATP concentration suggest that
the membrane provides a quite good biocompatible coverage.
After 30 days, ATP and neutrophil levels are comparable
with the negative control (AP), as well as for the commercial
chip, and significantly lower than the positive control (LPS),
proving that after 30 days the host seems to accept the implant.
Unfortunately, a cell layer covered the surface of the sensing
platform. Future steps will be the evaluation of the effect of
this cell layer on sensing performances and the application
of an anti-fouling agent on top of the membrane in order to
reduce the cell adhesion.
IV. CONCLUSIONS
In this work we showed the assembly into a fully-
implantable device of a microfabricated sensing platform, a
coil for power and data transmission and integrated circuits.
We described a device intended to test the biocompatibil-
ity of the material used for the microfabrication. Therefore,
no electronics measurements are reported here, while data
communication and remote powering measurements are the
objective of another paper [1]. Experimental results on bio-
sensing with the integrated device are ongoing. An epoxy
enhanced polyurethane membrane was used to cover the
device to ensure biocompatibility. An in-vitro characterization
proved that the membrane is capable to retain enzyme activity
up to 35 days. In-vivo experiment in mice proved that, after
30 days of implant, the membrane promotes the integration
of the sensor with the surrounding tissue, as demonstrated by
the low inflammation levels at the implant site. In conclusions
the epoxy enhanced polyurethane membrane is a promising
material for the realization of a biocompatible packaging for
implantable biosensors.
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